Lymphoma & Plasma Cell Disorders
News
Tenalisib receives orphan designation for CTCL
The US Food and Drug Administration (FDA) has granted orphan drug designation to tenalisib for treatment of cutaneous T-cell lymphoma (CTCL)....
News
Duvelisib NDA granted priority review
The US Food and Drug Administration (FDA) has accepted for priority review the new drug application (NDA) for duvelisib, a dual PI3K delta/gamma...
From the Journals
Updated CLL guidelines incorporate a decade of advances
Advances in genomics, diagnostics and therapies since 2008 are reflected in the guidelines.
News
Project provides ‘unprecedented understanding’ of cancers
Through extensive analyses of data from The Cancer Genome Atlas (TCGA), researchers have produced a new resource known as the Pan-Cancer Atlas....
News
Drug receives priority review for HCL
The US Food and Drug Administration (FDA) has accepted for priority review the biologics license application (BLA) for moxetumomab pasudotox, an...
From the Journals
Lenalidomide yields responses in a rare cutaneous lymphoma
Reduced doses of the drug showed the best results in the phase 2 trial.
News
CHMP supports expanded approval for fosaprepitant
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended changing the terms of marketing...
From the Journals
Ibrutinib plus venetoclax is active in mantle cell lymphoma
The combination appears to outperform the single agents when treating relapsed/refractory mantle cell lymphoma.
News
ICER assesses value of CAR T-cell therapies
The Institute for Clinical and Economic Review (ICER) has made policy recommendations intended to ensure affordability and access to chimeric...
News
Health Canada approves SC rituximab for CLL
Health Canada has approved a subcutaneous (SC) formulation of rituximab (Rituxan®) to treat patients with chronic lymphocytic leukemia (CLL). The...
From the Journals
Experimental voxtalisib shows mixed results in phase 2 study
The novel pan-P13K/mTOR inhibitor induced complete responses in some patients with follicular lymphoma, but not aggressive malignancies, including...